{"pages_annotated": [], "figures": [{"page_width": 612, "caption_text": ["Figure 1 Study population.", "Notes: Five randomized patients did not proceed with treatment: three patients decided to not participate, one patient developed a COPD exacerbation, and one patient", "was unable to stop prohibited medication prior to randomization.", "Abbreviations: N, number; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I+A, ipratropium", "bromide and albuterol metered dose inhalers delivered as dual monotherapies; AE, adverse event."], "figure_type": "Figure", "region_bb": [134, 454, 326, 213], "caption_bb": [53.0, 678.0, 449.0, 42.0], "page": 4, "page_height": 792}, {"page_width": 612, "caption_text": ["Figure 3 Adjusted mean of PASAPQ performance domain score time profile.", "Abbreviations: PASAPQ, Patient Satisfaction and Preference Questionnaire; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/", "albuterol metered-dose inhaler; I + A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies."], "figure_type": "Figure", "region_bb": [138, 69, 352, 221.0], "caption_bb": [70.0, 299.0, 447.0, 24.0], "page": 7, "page_height": 792}, {"page_width": 612, "caption_text": ["Figure 4 Kaplan-Meier curves for time to first COPD exacerbation.", "Abbreviations: COPD, chronic obstructive pulmonary disease; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol", "metered-dose inhaler; I+A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies; d, day."], "figure_type": "Figure", "region_bb": [128.0, 449, 369.0, 237.0], "caption_bb": [70.0, 696.0, 432.0, 24.0], "page": 7, "page_height": 792}, {"page_width": 612, "caption_text": ["Figure 4 Kaplan-Meier curves for time to first COPD exacerbation.", "Abbreviations: COPD, chronic obstructive pulmonary disease; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol", "metered-dose inhaler; I+A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies; d, day."], "figure_type": "Figure", "region_bb": [128.0, 449, 369.0, 237.0], "caption_bb": [70.0, 696.0, 432.0, 24.0], "page": 7, "page_height": 792}, {"page_width": 612, "caption_text": ["Figure 2 Kaplan\u2013Meier curves of time to discontinuation.", "Abbreviations: CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I + A, ipratropium bromide and", "albuterol metered dose inhalers delivered as dual monotherapies; d, days."], "figure_type": "Figure", "region_bb": [122.0, 463, 347.0, 223.0], "caption_bb": [53.0, 696.0, 449.0, 24.0], "page": 6, "page_height": 792}], "fig_no": 4}